Results 81 to 90 of about 7,013,774 (312)

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Spatiotemporal and quantitative analyses of phosphoinositides – fluorescent probe—and mass spectrometry‐based approaches

FEBS Letters, EarlyView.
Fluorescent probes allow dynamic visualization of phosphoinositides in living cells (left), whereas mass spectrometry provides high‐sensitivity, isomer‐resolved quantitation (right). Their synergistic use captures complementary aspects of lipid signaling. This review illustrates how these approaches reveal the spatiotemporal regulation and quantitative
Hiroaki Kajiho, Shin Morioka, Junko Sasaki, Takehiko Sasaki   +3 more
wiley   +1 more source

Methylglyoxal-induced RNA modifications decrease RNA stability and translation and are associated with type 2 diabetes

Molecular Metabolism
Objectives: Methylglyoxal (MG), a reactive aldehyde generated as a byproduct of glucose and lipid metabolism, is known to modify nucleic acids and proteins, altering their structure and function.
Edwin De Jesus Lopez Gonzalez, SWT Lai, Kelani Sun, Caree R. Carson, Carlos Hernandez-Castillo, Tala Zoukari, Kassandra Lopez, Jianying Zhang, Thomas Blevins, John Termini, Sarah C. Shuck   +10 more
doaj   +1 more source

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy

OncoImmunology, 2019
The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear ...
Sara Verdura, Elisabet Cuyàs, Begoña Martin-Castillo, Javier A. Menendez   +3 more
doaj   +1 more source

Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer

npj Precision Oncology, 2022
Triple-negative breast cancer (TNBC) patients receive chemotherapy treatment, including doxorubicin, due to the lack of targeted therapies. Drug resistance is a major cause of treatment failure in TNBC and therefore, there is a need to identify ...
Thomas J. Velenosi, Kristopher W. Krausz, Keisuke Hamada, Tiffany H. Dorsey, Stefan Ambs, Shogo Takahashi, Frank J. Gonzalez   +6 more
doaj   +1 more source

Protein pyrophosphorylation by inositol pyrophosphates — detection, function, and regulation

FEBS Letters, EarlyView.
Protein pyrophosphorylation is an unusual signaling mechanism that was discovered two decades ago. It can be driven by inositol pyrophosphate messengers and influences various cellular processes. Herein, we summarize the research progress and challenges of this field, covering pathways found to be regulated by this posttranslational modification as ...
Sarah Lampe, Tanmay Kumar Mohanty, Rashna Bhandari, Dorothea Fiedler   +3 more
wiley   +1 more source

Sphinganine recruits TLR4 adaptors in macrophages and promotes inflammation in murine models of sepsis and melanoma

Nature Communications
After recognizing its ligand lipopolysaccharide, Toll-like receptor 4 (TLR4) recruits adaptor proteins to the cell membrane, thereby initiating downstream signaling and triggering inflammation.
Marvin Hering, Alaa Madi, Roger Sandhoff, Sicong Ma, Jingxia Wu, Alessa Mieg, Karsten Richter, Kerstin Mohr, Nora Knabe, Diana Stichling, Gernot Poschet, Felix Bestvater, Larissa Frank, Jochen Utikal, Viktor Umansky, Guoliang Cui   +15 more
doaj   +1 more source

Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer

OncoImmunology, 2017
Kynurenine formation by tryptophan-catabolic indoleamine-2,3-dioxygenase 1 (IDO1) plays a key role in tumor immune evasion and inhibition of IDO1 is efficacious in preclinical models of breast cancer. As the response of breast cancer to immune checkpoint
Dyah L. Dewi, Soumya R. Mohapatra, Saioa Blanco Cabañes, Isabell Adam, Luis F. Somarribas Patterson, Bianca Berdel, Masroor Kahloon, Loreen Thürmann, Stefanie Loth, Katharina Heilmann, Dieter Weichenhan, Oliver Mücke, Ines Heiland, Pauline Wimberger, Jan Dominik Kuhlmann, Karl-Heinz Kellner, Sarah Schott, Christoph Plass, Michael Platten, Clarissa Gerhäuser, Saskia Trump, Christiane A. Opitz   +21 more
doaj   +1 more source

IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer

npj Breast Cancer, 2021
Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative.
Claudia Tulotta, Diane V. Lefley, Charlotte K. Moore, Ana E. Amariutei, Amy R. Spicer-Hadlington, Lewis A. Quayle, Russell O. Hughes, Khawla Ahmed, Victoria Cookson, Catherine A. Evans, Jayakumar Vadakekolathu, Paul Heath, Sheila Francis, Emmanuel Pinteaux, A. Graham Pockley, Penelope D. Ottewell   +15 more
doaj   +1 more source

Cancer metabolism: a therapeutic perspective

Nature Reviews Clinical Oncology, 2017
Awareness that the metabolic phenotype of cells within tumours is heterogeneous — and distinct from that of their normal counterparts — is growing. In general, tumour cells metabolize glucose, lactate, pyruvate, hydroxybutyrate, acetate, glutamine, and ...
U. Martinez-Outschoorn, Maria Peiris‐Pagès, R. Pestell, F. Sotgia, M. Lisanti   +4 more
semanticscholar   +1 more source